Boehringer Launches Gilotrif At $5,500/Month, Just Under Entrenched Tarceva
This article was originally published in The Pink Sheet Daily
Executive Summary
It’s become commonplace to see monthly pricing of $10,000 for new cancer drugs, but with competition in mind Boehringer takes a conservative approach with its non-small-cell lung cancer drug Gilotrif (afatinib).
You may also be interested in...
Keeping Track: FDA Hands Out Complete Responses, Expedited Pathway Designations
The latest US drug development news and highlights from our Performance Tracker.
Boehringer’s Oncology Strategy: Build From Niche Lung Cancer Base
With Gilotrif sales building over time, private Boehringer Ingelheim turns its focus to broad development program for its third-generation EGFR inhibitor olmutinib, with ambition to become a leader in lung cancer.
Head-To-Head Lung Data Support Boehringer’s Gilotrif Over Iressa
Final results from the LUX-Lung 7 trial suggest superior efficacy for Boehringer’s EGFR inhibitor Gilotrif vs. AstraZeneca’s Iressa, albeit with a small absolute improvement in progression-free survival and a higher rate of severe diarrhea.